Intellia Therapeutics, Inc (NTLA) Financials
Key financial figures for Intellia Therapeutics, Inc (Q2 2026).
Intellia Therapeutics, Inc. reported revenue of $7.7 million for Q2 FY2026, down 46.2% from the same period a year earlier. The company posted a net loss of $106.6 million, or -$0.80 per share. Operating margin came to -1472.25%, against -772.17% a year earlier. Free cash flow for the period was -$84.9 million. Across the last 5 reported quarters, quarterly revenue has moved from $14.2 million in Q2 FY2025 to $7.7 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Intellia Therapeutics, Inc. are on the SentiSense financials page.
- Revenue
- $8M
- Net Income
- -$107M
- EPS
- $-0.80
- Total Assets
- $857M
- Operating Cash Flow
- -$83M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $8M | -$107M | -$0.80 | -1472.25% | -$85M |
| Q1 FY2026 | $15M | -$96M | -$0.81 | -668.08% | -$117M |
| Q4 FY2025 | $23M | -$96M | -$0.83 | -428.86% | -$69M |
| Q3 FY2025 | $14M | -$101M | -$0.92 | -808.86% | -$77M |
| Q2 FY2025 | $14M | -$101M | -$0.98 | -772.17% | -$100M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $68M | -$413M | -$3.81 | -651.67% | -$355M |
| FY2024 | $58M | -$519M | -$5.25 | -923.1% | -$355M |
| FY2023 | $36M | -$481M | -$5.42 | -1420.51% | -$408M |
Frequently asked questions
What was Intellia Therapeutics, Inc.'s revenue last quarter?
Intellia Therapeutics, Inc. reported revenue of $7.7 million for Q2 FY2026, down 46.2% from the same period a year earlier.
Is Intellia Therapeutics, Inc. profitable?
Not in its most recent reported period. Intellia Therapeutics, Inc. reported a net loss of $106.6 million for Q2 FY2026, a net margin of -1392.27% on revenue.
How has Intellia Therapeutics, Inc.'s margin trended?
Operating margin was -1472.25% in Q2 FY2026, compared with -772.17% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Intellia Therapeutics, Inc. generate?
Intellia Therapeutics, Inc. generated free cash flow of -$84.9 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Intellia Therapeutics, Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.